IP Library › Granted Patent US 12,410,402
Granted Patent B2
US 12,410,402 · App. 17/295,849 · Granted Sep 9, 2025

Methods for expansion of natural killer (NK) cell subset and related compositions and methods

Inventors: Austin Bigley (Houston, TX); Ronald Martell (San Francisco, CA); Guy Dipierro (Houston, TX)
Assignee: INDAPTA THERAPEUTICS, INC.
C12N5/0646A61K40/15A61K40/428A61K2239/31A61K2239/38A61K2239/48A61K2239/59C12N2501/2302C12N2501/50C12N2502/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,410,402
App. No.
17/295,849
Granted
Sep 9, 2025
Kind
B2
Abstract

Provided herein are methods for ex vivo expansion of a specialized subset of natural killer (NK) cells, and compositions containing such NK cells. Also provided are methods for identifying or detecting a specialized subset of NK cells. Also provided are methods for treating diseases and conditions such as cancer using provided compositions, including in combination with an antibody capable of binding to disease-associated tissues or cells, such as tumor cells or infected cells.

Claims (65)

1. A method for expanding FcRγ-deficient NK cells (g-NK), said method comprising:

(a) isolating a population of primary human cells enriched for natural killer (NK) cells, the isolating comprises selecting from a sample from a human subject: (i) cells negative for CD3 and positive for CD57 (CD3 neg CD57 pos ); (ii) cells negative for CD3, positive for CD56, and negative for CD38 (CD3 neg CD56 pos CD38 neg ); (iii) cells negative for CD3 (CD3 neg ); (iv) cells negative for CD3 (CD3 neg ) and positive for CD56 (CD3 neg CD56 pos ); (v) cells negative for CD3 and positive for CD16 (CD3 neg CD16 pos ); or (vi) cells negative for CD3, positive for CD56, negative for NKG2A and negative for CD161 (CD3 neg CD56 pos NKG2A neg CD161 neg ); and

(b) culturing the population of enriched NK cells in the presence of (i) irradiated 221.AEH feeder cells, wherein the ratio of irradiated 221.AEH feeder cells to enriched NK cells is between at or about 1:2.5 and at or about 5:1, inclusive; and (ii) recombinant IL-2,

wherein the method produces an expanded population of g-NK cells.

2. The method of claim 1 , wherein the human subject is CMV seropositive.

3. The method of claim 1 , wherein the human subject has the CD16 158V+ NK cell genotype.

4. The method of claim 1 , wherein the sample is or comprises peripheral blood mononuclear cells (PBMCs).

5. The method of claim 1 , wherein the sample is an apheresis or leukaphereis sample.

6. The method of claim 1 , wherein the isolating is of (i) and comprises selecting from the sample cells negative for CD3 and positive for CD57 (CD3 neg CD57 pos ).

7. The method of claim 1 , wherein after (a) cryopreserving the isolated population of enriched NK cells and prior to (b) thawing the cryopreserved sample comprising the enriched NK cells.

8. The method of claim 1 , wherein the culturing is further carried out in the presence of (iii) primary human peripheral blood mononuclear cells (PBMCs) feeder cells, wherein the PBMC feeder cells are irradiated.

9. The method of claim 8 , wherein at least a portion of the culturing is carried out in the presence of at least one stimulatory agent that is capable of stimulating the activation of one or more T cell of the PBMC feeder cells.

10. The method of claim 1 , wherein the ratio of irradiated AEH.221 feeder cells to enriched NK cell is between 1:1 and 3:1, inclusive.

11. The method of claim 1 , wherein the concentration of recombinant IL-2 during at least a portion of the culturing is between at or about 10 IU/mL and at or about 500 IU/mL.

12. The method of claim 1 , wherein the population of enriched NK cells at the initiation of the culturing is at a concentration of between at or about 0.05×10 6 enriched NK cells/mL and at or about 1.0×10 6 enriched NK cells/mL.

13. The method of claim 1 , wherein the population of enriched NK cells at the initiation of the culturing is at a concentration of between at or about 0.05×10 6 enriched NK cells/mL and at or about 0.5×10 6 enriched NK cells/mL.

14. The method of claim 1 , wherein the culturing is carried out for at or about or at least at or about 14 days.

15. The method of claim 1 , wherein the culturing is carried out for at or about or at least at or about 21 days.

16. The method of claim 1 , wherein the method produces an increased number of g-NK cells at the end of the culturing compared to at the initiation of the culturing, and wherein the increase is greater than or greater than about 100-fold.

17. The method of claim 1 , wherein after the culturing collecting the expanded population of g-NK cells produced by the method.

18. The method of claim 17 , further comprising formulating the collected expanded population of g-NK cells in a pharmaceutically acceptable excipient.

19. The method of claim 17 , further comprising formulating the collected expanded population of g-NK cells in the presence of a cryoprotectant.

20. The method of claim 1 , wherein the culturing the NK cells comprises one or more additional cytokines for the expansion of the NK cells, wherein the one or more additional cytokines is recombinant IL-21, recombinant IL-18, recombinant IL-7, recombinant IL-15, and/or recombinant IL-12.

21. The method of claim 1 , wherein the isolating is of (iv) and comprises selecting from the sample cells negative for CD3 and positive for CD56 (CD3 neg CD56 pos ).

22. The method of claim 19 , further comprising cryopreserving the cells.

23. A method for expanding FcRγ-deficient NK cells (g-NK), said method comprising:

(a) isolating a population of primary human cells enriched for natural killer (NK) cells, the isolating comprises selecting from a sample from a human subject: (i) cells negative for CD3 and positive for CD57 (CD3 neg CD57 pos ); (ii) cells negative for CD3, positive for CD56, and negative for CD38 (CD3 neg CD56 pos CD38 neg ); (iii) cells negative for CD3 (CD3 neg ); (iv) cells negative for CD3 (CD3 neg ) and positive for CD56 (CD3 neg CD56 pos ); (v) cells negative for CD3 and positive for CD16 (CD3 neg CD16 pos ); or (vi) cells negative for CD3, positive for CD56, negative for NKG2A and negative for CD161 (CD3 neg CD56 pos NKG2A neg CD161 neg );

(b) combining the population of enriched NK cells with irradiated 221.AEH feeder cells and irradiated peripheral blood mononuclear (PBMC) feeder cells, wherein the ratio of irradiated 221.AEH feeder cells to enriched NK cells is between at or about 1:2.5 and at or about 5:1, inclusive and the ratio of PBMC feeder cells to enriched NK cells is between at or about 1:1 and at or about 5:1, inclusive;

(c) culturing the population of (b) in the presence of recombinant IL-2 and an anti-CD3 antibody or antigen-binding fragment, wherein, within 7 days of initiation of the culturing, exchanging the cell culture media with fresh media containing recombinant IL-2; and

(d) collecting the expanded population of cells.

24. The method of claim 23 , wherein the human subject is CMV seropositive.

25. A method for expanding FcRγ-deficient NK cells (g-NK), said method comprising:

(a) obtaining a population of primary human cells enriched for natural killer (NK) cells that have been selected from a sample from a human subject for cells that comprise a phenotype selected from: (i) cells negative for CD3 and positive for CD57 (CD3 neg CD57 pos ); (ii) cells negative for CD3, positive for CD56, and negative for CD38 (CD3 neg CD56 pos CD38 neg ); (iii) cells negative for CD3 (CD3 neg ); (iv) cells negative for CD3 (CD3 neg ) and positive for CD56 (CD3 neg CD56 pos ); (v) cells negative for CD3 and positive for CD16 (CD3 neg CD16 pos ) or (vi) cells negative for CD3, positive for CD56, negative for NKG2A and negative for CD161 (CD3 neg CD56 pos NKG2A neg CD161 neg ); and

(b) culturing the population of enriched NK cells in the presence of (i) irradiated 221.AEH feeder cells, wherein the ratio of irradiated 221.AEH feeder cells to enriched NK cells is between at or about 1:2.5 and at or about 5:1, inclusive; and (ii) recombinant IL-2,

wherein the method produces an expanded population of NK cells enriched for g-NK cells.

26. The method of claim 25 , wherein the human subject is CMV seropositive.

27. The method of claim 25 , wherein the population of enriched NK cells have been selected for cells negative for CD3 and positive for CD56 (CD3 neg CD56 pos ).

28. The method of claim 25 , wherein the human subject has the CD16 158V+ NK cell genotype.

29. The method of claim 25 , wherein the sample is or comprises peripheral blood mononuclear cells (PBMCs).

30. The method of claim 25 , wherein the culturing the NK cells comprises one or more additional cytokines for the expansion of the NK cells, wherein the one or more additional cytokines is recombinant IL-21, recombinant IL-18, recombinant IL-7, recombinant IL-15, and/or recombinant IL-12.

31. The method of claim 25 , wherein the ratio of irradiated AEH.221 feeder cells to enriched NK cell is between 1:1 and 3:1, inclusive.

32. A method for expanding FcRγ-deficient NK cells (g-NK), the method comprising culturing a population of primary human cells enriched for natural killer (NK) cell from a sample from a CMV seropositive human subject, the population of enriched NK cells having been selected from a sample from a human subject for cells negative for CD3 and positive for CD57, wherein the culturing is carried out in the presence of:

(i) irradiated 221.AEH feeder cells, wherein the ratio of irradiated 221.AEH feeder cells to enriched NK cells is between at or about 1:2.5 and at or about 5:1, inclusive; and

(ii) recombinant IL-2;

wherein the method produces an expanded population of g-NK cells.

33. A method for expanding FcRγ-deficient NK cells (g-NK), the method comprising culturing a population of primary human cells enriched for natural killer (NK) cell from a sample from a CMV seropositive human subject, the population of enriched NK cells having been selected from a sample from a human subject for cells negative for CD3, positive for CD56, and negative for CD38, wherein the culturing is carried out in the presence of:

(i) irradiated 221.AEH feeder cells, wherein the ratio of irradiated 221.AEH feeder cells to enriched NK cells is between at or about 1:2.5 and at or about 5:1, inclusive; and

(ii) recombinant IL-2;

wherein the method produces an expanded population of g-NK cells.

34. A method for expanding FcRγ-deficient NK cells (g-NK), the method comprising culturing a population of primary human cells enriched for natural killer (NK) cells from a sample from a CMV seropositive human subject, the population of enriched NK cells having been selected from a sample from a human subject for cells negative for CD3 and positive for CD16, wherein the culturing is carried out in the presence of:

(i) irradiated 221.AEH feeder cells, wherein the ratio of irradiated 221.AEH feeder cells to enriched NK cells is between at or about 1:2.5 and at or about 5:1, inclusive; and

(ii) recombinant IL-2,

wherein the method produces an expanded population of g-NK cells.

35. A method for expanding FcRγ-deficient NK cells (g-NK), the method comprising culturing a population of primary human cells enriched for natural killer (NK) cells from a sample from a CMV seropositive human subject, the population of enriched NK cells having been selected from a sample from a human subject for cells negative for CD3, positive for CD56, negative for NKG2A and negative for CD161, wherein the culturing is carried out in the presence of:

(i) irradiated 221.AEH feeder cells, wherein the ratio of irradiated 221.AEH feeder cells to enriched NK cells is between at or about 1:2.5 and at or about 5:1, inclusive; and

(ii) recombinant IL-2,

wherein the method produces an expanded population of g-NK cells.

36. A method for expanding FcRγ-deficient NK cells (g-NK), the method comprising culturing a population of primary human cells enriched for natural killer (NK) cell from a sample from a CMV seropositive human subject, the population of enriched NK cells having been selected from a sample from a human subject for cells negative for CD3 and positive for CD56, wherein the culturing is carried out in the presence of:

(i) irradiated 221.AEH feeder cells, wherein the ratio of irradiated 221.AEH feeder cells to enriched NK cells is from 1:2.5 and at or about 5:1; and

(ii) recombinant IL-2;

wherein the method produces an expanded population of g-NK cells.

37. The method of claim 36 , wherein the human subject has the CD16 158V+ NK cell genotype.

38. The method of claim 36 , wherein the sample is or comprises peripheral blood mononuclear cells (PBMCs).

39. The method of claim 36 , wherein the culturing the NK cells comprises one or more additional cytokines for the expansion of the NK cells, wherein the one or more additional cytokines is recombinant IL-21, recombinant IL-18, recombinant IL-7, recombinant IL-15, and/or recombinant IL-12.

40. The method of claim 36 , wherein the ratio of irradiated AEH.221 feeder cells to enriched NK cell is between 1:1 and 3:1, inclusive.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2023
From: BIGLEY, AUSTIN; MARTELL, RONALD; DIPIERRO, GUY
To: INDAPTA THERAPEUTICS, INC.
Reel/Frame 062932/0711 →
Continuity (2)
Provisional Application 62770686 · Nov 21, 2018
Related Publication 20220008466A1 · Jan 13, 2022
References Cited (215)
US 4683195A · Mullis et al. · 1987 [cited by applicant]
US 4683202A · Mullis · 1987 [cited by applicant]
US 4889818A · Gelfand et al. · 1989 [cited by applicant]
US 5641870A · Rinderknecht et al. · 1997 [cited by applicant]
US 5716613A · Guber et al. · 1998 [cited by applicant]
US 5716826A · Gruber et al. · 1998 [cited by applicant]
US 5851529A · Guber et al. · 1998 [cited by applicant]
US 6168991B1 · Choi et al. · 2001 [cited by applicant]
US 6428968B1 · Molnar-Kimber et al. · 2002 [cited by applicant]
US 6632670B1 · Wadsworth et al. · 2003 [cited by applicant]
US 6635472B1 · Lauermann · 2003 [cited by applicant]
US 6653103B2 · Petersen et al. · 2003 [cited by applicant]
US 6689871B1 · Wolfe et al. · 2004 [cited by applicant]
US 6723316B2 · Laquerre et al. · 2004 [cited by applicant]
US 6897045B2 · Engelhardt et al. · 2005 [cited by applicant]
US 7001765B2 · Maass et al. · 2006 [cited by applicant]
US 7033826B2 · Perricaudet et al. · 2006 [cited by applicant]
US 7153510B1 · Rose · 2006 [cited by applicant]
US 7172893B2 · Rabinowitz et al. · 2007 [cited by applicant]
US 7238526B2 · Wilson et al. · 2007 [cited by applicant]
US 7241447B1 · Engelhardt et al. · 2007 [cited by applicant]
US 7537924B2 · Coffin · 2009 [cited by applicant]
US 7550296B2 · Hermiston et al. · 2009 [cited by applicant]
US 7588767B2 · Szalay et al. · 2009 [cited by applicant]
US 7588771B2 · Szalay et al. · 2009 [cited by applicant]
US 7662398B2 · Szalay et al. · 2010 [cited by applicant]
US 7662627B2 · Johnson et al. · 2010 [cited by applicant]
US 7731952B2 · Mohr et al. · 2010 [cited by applicant]
US 7731974B2 · Bell et al. · 2010 [cited by applicant]
US 7754221B2 · Szalay et al. · 2010 [cited by applicant]
US 7811814B2 · Bohn et al. · 2010 [cited by applicant]
US 7897146B2 · Brown et al. · 2011 [cited by applicant]
US 7906111B2 · Wilson et al. · 2011 [cited by applicant]
US 7927585B2 · Snyder · 2011 [cited by applicant]
US 7943374B2 · Hildinger · 2011 [cited by applicant]
US 7968340B2 · Hallek et al. · 2011 [cited by applicant]
US 8007780B2 · Arbetman · 2011 [cited by applicant]
US 10066207B2 · Kim et al. · 2018 [cited by applicant]
US 11471486B2 · Malmberg · 2022 [cited by examiner]
US 20040009604A1 · Zhang et al. · 2004 [cited by applicant]
US 20040063094A1 · Coffin et al. · 2004 [cited by applicant]
US 20050220818A1 · Lorence · 2005 [cited by applicant]
US 20050260601A1 · Whitt · 2005 [cited by applicant]
US 20060039894A1 · Mohr et al. · 2006 [cited by applicant]
US 20060292156A1 · Campbell · 2006 [cited by applicant]
US 20070098743A1 · Bell et al. · 2007 [cited by applicant]
US 20070110720A1 · Brown et al. · 2007 [cited by applicant]
US 20070202572A1 · Szalay et al. · 2007 [cited by applicant]
US 20070212727A1 · Szalay et al. · 2007 [cited by applicant]
US 20090010889A1 · Brown et al. · 2009 [cited by applicant]
US 20090053244A1 · Chen et al. · 2009 [cited by applicant]
US 20090098529A1 · Chen et al. · 2009 [cited by applicant]
US 20090117034A1 · Chen et al. · 2009 [cited by applicant]
US 20090136917A1 · Szalay et al. · 2009 [cited by applicant]
US 20090155287A1 · Chen et al. · 2009 [cited by applicant]
US 20090162288A1 · Chen et al. · 2009 [cited by applicant]
US 20090215147A1 · Zhang et al. · 2009 [cited by applicant]
US 20090274728A1 · Brown et al. · 2009 [cited by applicant]
US 20090285860A1 · Martuza et al. · 2009 [cited by applicant]
US 20100062016A1 · Szalay et al. · 2010 [cited by applicant]
US 20100092515A1 · Conner et al. · 2010 [cited by applicant]
US 20100113567A1 · Barber · 2010 [cited by applicant]
US 20100172877A1 · Van Den Pol · 2010 [cited by applicant]
US 20100178684A1 · Woo et al. · 2010 [cited by applicant]
US 20100196325A1 · Szalay et al. · 2010 [cited by applicant]
US 20100233078A1 · Szalay et al. · 2010 [cited by applicant]
US 20110064650A1 · Szalay · 2011 [cited by applicant]
US 20110158948A1 · Brown et al. · 2011 [cited by applicant]
US 20110177032A1 · Martuza et al. · 2011 [cited by applicant]
US 20110212530A1 · Baltimore et al. · 2011 [cited by applicant]
US 20130295044A1 · Kim et al. · 2013 [cited by applicant]
US 20140154216A1 · Coffin · 2014 [cited by applicant]
US 20160339066A1 · Szalay et al. · 2016 [cited by applicant]
US 20170137784A1 · Masuyama · 2017 [cited by applicant]
US 20180057795A1 · Childs · 2018 [cited by examiner]
US 20190376036A1 · DiPierro · 2019 [cited by applicant]
EP 1385466 · 2004 [cited by applicant]
EP 1520175 · 2005 [cited by applicant]
EP 1606411 · 2005 [cited by applicant]
EP 3539553 · 2019 [cited by applicant]
JP 2002504357A · 2002 [cited by applicant]
JP 2010524500A · 2010 [cited by applicant]
JP 2011529341 · 2011 [cited by applicant]
JP 2012521215A · 2012 [cited by applicant]
JP 2019170176A · 2019 [cited by applicant]
WO WO1999038955 · 1999 [cited by applicant]
WO WO1999043208A1 · 1999 [cited by applicant]
WO WO2007052029 · 2007 [cited by applicant]
WO WO2009041113A1 · 2009 [cited by applicant]
WO WO2010110734 · 2010 [cited by applicant]
WO WO2012061814 · 2012 [cited by applicant]
WO WO2014145252A2 · 2014 [cited by applicant]
WO WO2014189628A1 · 2014 [cited by applicant]
WO WO2016011210A2 · 2016 [cited by applicant]
WO WO2016077734A2 · 2016 [cited by applicant]
WO WO2016151741A1 · 2016 [cited by applicant]
WO WO2016201300A1 · 2016 [cited by applicant]
WO WO2017001572A1 · 2017 [cited by applicant]
WO WO2017017184A1 · 2017 [cited by applicant]
WO WO2017048809A1 · 2017 [cited by applicant]
WO WO2017078807A1 · 2017 [cited by applicant]
WO WO2017079673A1 · 2017 [cited by applicant]
WO WO2017127729A1 · 2017 [cited by applicant]
WO WO2017127755A1 · 2017 [cited by applicant]
WO WO2018148462 · 2018 [cited by applicant]
WO WO2019222293 · 2019 [cited by applicant]
WO WO2020107002 · 2020 [cited by applicant]
Bigley et al., “Latent cytomegalovirus infection enhances anti-tumour cytotoxicity through accumulation of NKG2C+ NK cells in healthy humans,” Clin Exp Immunol. (2016) 185(2): 239-51. (Year: 2016). [cited by examiner]
Fujisaki, Hiroyuki et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009; 69: (9). pp. 4010-4017. (Year: 2009). [cited by examiner]
Allen et al., “Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity,” Cancer Res. (2006) 66(24): 11840-50. [cited by applicant]
Amersdorfer et al., “Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries,” Infect Immun. (1997) 65(9): 3743-52. [cited by applicant]
Bae et al., “Extracellular matrix for a rechargeable cell delivery system,” J Control Release. (1998) 53(1-3): 249-58. [cited by applicant]
Benecia et al., “HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer,” Mol Ther. (2005) 12(5): 789-802. [cited by applicant]
Bhat et al., “Enhancement of NK cell antitumor responses using an oncolytic parvovirus,” Int J Cancer. (2011) 128(4): 908-19. [cited by applicant]
Bhat et al., “NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells,” BMC Cancer. (2013) 13:367. [cited by applicant]
Bigley et al., “Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells,” Brain Behav Immun. (2014) 39:160-71. [cited by applicant]
Bigley et al., “NK cell function is impaired during long-duration spaceflight,” J Appl Physiol. (2018) 126:842-853. [cited by applicant]
Bigley et al., “Latent cytomegalovirus infection enhances anti-tumour cytotoxicity through accumulation of NKG2C+ NK cells in healthy humans,” Clin Exp Immunol. (2016) 185(2): 239-51. [cited by applicant]
Bigley et al., “Cytomegalovirus: an unlikely ally in the fight against blood cancers?,” Clin Exp Immunol. (2018) 193(3): 265-274. [cited by applicant]
Boerner et al., “Production of Antigen-Specific Human Monoclonal Antibodies From in Vitro-Primed Human Splenocytes,” J Immunol (1991) 147 (1), 86-95 (Abstract only). [cited by applicant]
Bottino et al., “NK cell activating receptors and tumor recognition in humans,” Curr Top Microbiol Immunol. (2006) 298: 175-182. [cited by applicant]
Bouhadir et al., “Degradation of partially oxidized alginate and its potential application for tissue engineering,” Biotechnol Prog. (2001) 17(5): 945-50. [cited by applicant]
Bryant et al., “The effects of scaffold thickness on tissue engineered cartilage in photocrosslinked poly(ethylene oxide) hydrogels,” Biomaterials. (2001) 22(6): 619-26. [cited by applicant]
Bryceson et al., “Line of attack: NK cell specificity and integration of signals,” Curr Opin Immunol. (2008) 20(3): 344-352. [cited by applicant]
Caligiuri et al., “Human natural killer cells,” Blood. Aug. 1, 2008;112(3):461-469. [cited by applicant]
Capuano et al., “Tumor-Targeting Anti-CD20 Antibodies Mediate In Vitro Expansion of Memory Natural Killer Cells: Impact of CD16 Affinity Ligation Conditions and In Vivo Priming,” Front Immunol. (2018) 9:1031. [cited by applicant]
Cartron et al., “Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in lgG Fc receptor FcgammaRIIa gene,” Blood. (2002) 99(3): 754-758. [cited by applicant]
Chen et al., “Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms,” Infect Immun. (1997) 65(5):1626-30. [cited by applicant]
Chomczynski et al., “Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction,” Anal Biochem. (1987) 162(1):156-159. [cited by applicant]
Cooley et al., “First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia,” Blood Adv. (2019) 3(13):1970-1980. [cited by applicant]
Dempe et al., “Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment,” Cancer Immunol Immunother. (2012) 61(11): 2113-23. [cited by applicant]
Finnern et al., “Human autoimmune anti-proteinase 3 scFv from a phage display library,” Clin Exp Immunol. (1997) 107(2): 269-81. [cited by applicant]
Fishwild et al., “High-avidity human IgGK monoclonal antibodies from a novel strain of minilocus transgenic mice,” Nature Biotechnology (1996) 14:845-851. [cited by applicant]
Foley et al., “Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function,” Blood. (2012) 119(11): 2665-2674. [cited by applicant]
Fujisaki et al., “Expansion of highly cytotoxic human natural killer cells for cancer cell therapy,” Cancer Res. (2009) 69(9): 4010-4017. [cited by applicant]
Gappa et al., “The effect of zinc-crystallized glucagon-like peptide-1 on insulin secretion of macroencapsulated pancreatic islets,” Tissue Eng. (2001) 7(1): 35-44. [cited by applicant]
Garcia et al., “Human T cell receptor-mediated recognition of HLA-E,” Eur J Immunol. (2002) 32(4): 936-44. [cited by applicant]
Garcia-Aragoncillo et al., “Design of virotherapy for effective tumor treatment,” Curr Opin Mol Ther. (2010) 12(4): 403-11. [cited by applicant]
Gujar et al., “Oncolytic virus-initiated protective immunity against prostate cancer,” Mol Ther. (2011) 19(4): 797-804. [cited by applicant]
Hallden et al., “Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets,” Expert Opin Ther Targets. (2012) 16(10): 945-58. [cited by applicant]
Hatjiharissi et al., “Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism,” Blood. (2007) 110(7… [cited by applicant]
Heiber et al., “Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent,” J Virol. (2011) 85(20):10440-50. [cited by applicant]
Hoogenboom et al., “Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains,” Nucleic Acids Res. (1991) 19(15):4133-4137. [cited by applicant]
Hwang et al., “Identification of human NK cells that are deficient for signaling adaptor FcRγ and specialized for antibody-dependent immune functions,” Int Immunol. (2012) 24(12): 793-802. [cited by applicant]
Jarahian et al., “Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase,” J Virol. (2009) 83(16): 8108-21. [cited by applicant]
Jeong et al., “Thermogelling biodegradable copolymer aqueous solutions for injectable protein delivery and tissue engineering,” Biomacromolecules. (2002) 3(4):865-8. [cited by applicant]
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,” Nature (1986) 321(6069):522-525. [cited by applicant]
Kim et al., “FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma,” Blood. (2006) 108(8) :2720-2725. [cited by applicant]
Kim et al., “Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer,” Nat Rev Cancer. (2009) 9(1): 64-71. [cited by applicant]
Koene et al., “FcγRIIIa-158V/F Polymorphism Influences the Binding of lgG by Natural Killer Cell FcyRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype,” Blood. (1997) 90(3): 1109-1114. [cited by applicant]
Lahiji et al., “Chitosan supports the expression of extracellular matrix proteins in human osteoblasts and chondrocytes,” J Biomed Mater Res. (2000) 51(4): 586-95. [cited by applicant]
Lanier, “Up on the tightrope: natural killer cell activation and inhibition,” Nat Immunol. (2008) 9(5): 495-502. [cited by applicant]
Lee et al., “Preparation of poly(vinyl alcohol)-chondroitin sulfate hydrogel as matrices in tissue engineering,” Carbohydrate Polymers. (2005) 61: 348. [cited by applicant]
Lee et al., “The effects of cross-linking of collagen-glycosaminoglycan scaffolds on compressive stiffness, chondrocyte-mediated contraction, proliferation and biosynthesis,” Biomaterials. (2001) 22(23): 3145-3154. [cited by applicant]
Lee et al., “HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences,” J Immunol. (1998) 160(10): 4951-60. [cited by applicant]
Lonberg et al., “Human antibodies from transgenic mice,” Int Rev Immunol. (1995) 13(1): 65-93. [cited by applicant]
Lonberg et al., “Antigen-specific human antibodies from mice comprising four distinct genetic modifications,” Nature (1994) 368(6474):856-859. [cited by applicant]
Mann et al., “Smooth muscle cell growth in photopolymerized hydrogels with cell adhesive and proteolytically degradable domains: synthetic ECM analogs for tissue engineering,” Biomaterials. (2001) 22(22): 3045-51. [cited by applicant]
Marks et al., “Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system,” J Biol Chem. (1992) 267(23): 16007-16010. [cited by applicant]
Marks et al., “By-passing immunization. Human antibodies from V-gene libraries displayed on phage,” J Mol Bio (1991) 222(3):581-597. [cited by applicant]
McLoughlin et al., “TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up,” Ann Surg Oncol. (2005) 12… [cited by applicant]
Mellor et al., “A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer,” J Hematol Oncol. (2013) 6: 1. [cited by applicant]
Miller et al., “Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model,” Mol Ther. (2003) 7(6):741-7. [cited by applicant]
Miyamoto et al., “Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma,” Cancer Res. (2012) 72(10): 2609-21. [cited by applicant]
Musolino et al., “Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer,” J Clin Oncol. (2008) 26(11): 1789-17… [cited by applicant]
Ogbomo et al., “Tumor cells infected with oncolytic influenza A virus prime natural killer cells for lysis of resistant tumor cells,” Med Microbiol Immunol. (2010) 199(2): 93-101. [cited by applicant]
Ravetch et al. “lgG Fc Receptors,” Annu. Rev. Immunol. (2001) 19: 275-290. [cited by applicant]
Reisfeld and Sell, “Monoclonal antibodies and cancer therapy” (1985) Conference https://www.osti.gov/biblio/6081141. [cited by applicant]
Reichmann et al. “Reshaping human antibodies for therapy,” Nature (1988) 3 32(6162):323-327. [cited by applicant]
Rintoul et al., “ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic,” Mol Ther. (2012) 20(6): 1148-57. [cited by applicant]
Roda et al., “Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells,” Cancer Res. (2006) 66(1): 517-526. [cited by applicant]
Saiki et al., “Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes,” Nature. (1986) 324(6093):163-6. [cited by applicant]
Schlums et al., “Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function,” Immunity. (2015) 42(3): 443-456. [cited by applicant]
Shah et al., “Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity,” PLoS One. (2013) 8(10):e76781. [cited by applicant]
Smidsrød et al., “Alginate as immobilization matrix for cells,” Trends Biotechnol. (1990) 8(3): 71-78. [cited by applicant]
Somboonyosdech et al., “Correlation of FcγRIIIa polymorphisms and responses to rituximab in Thai population,” Asian Biomedicine (2012) 6(6):883-889. [cited by applicant]
Stewart et al., “Strategies of natural killer cell recognition and signaling,” Curr Top Microbiol Immunol. (2006) 298: 1-21. [cited by applicant]
Suggs et al., “Development of poly(propylene fumarate-co-ethylene glycol) as an injectable carrier for endothelial cells,” Cell Transplant. (1999) 8(4):345-50. [cited by applicant]
Suh et al., “Application of chitosan-based polysaccharide biomaterials in cartilage tissue engineering: a review,” Biomaterials. (2000) 21(24): 2589-98. [cited by applicant]
Tai et al., “Attacking Postoperative Metastases using Perioperative Oncolytic Viruses and Viral Vaccines,” Front Oncol. (2014) 4: 217. [cited by applicant]
Tate et al., “Biocompatibility of methylcellulose-based constructs designed for intracerebral gelation following experimental traumatic brain injury,” Biomaterials. (2001) 22(10): 1113-23. [cited by applicant]
Tomasec et al., “Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40,” Science. (2000) 287(5455): 1031. [cited by applicant]
Verhoyen et al., “Reshaping human antibodies: grafting an antilysozyme activity,” Science (1998) 239(4847):1534-1536. [cited by applicant]
Vivier et al., “Innate or adaptive immunity? The example of natural killer cells,” Science. (2011) 331(6013): 44-49. [cited by applicant]
White et al., “Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial,” Gene Ther. (2008) 15(12): 911-20. [cited by applicant]
Zapata et al., “Engineering Linear F(ab')2 Fragments For Efficient Production In [cited by applicant]
Zhang et al., “Antibody-dependent memory-like NK cells distinguished by FcRγ-deficiency,” J Immunol. (2013) 190(4): 1402-1406. [cited by applicant]
Zhao et al., “A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity,” PLoS One. (2014) 9(3): e93103. [cited by applicant]
Liu et al., “FcRγ Gene Editing Reprograms Conventional NK Cells to Display Key Features of Adaptive Human NK Cells,” iScience (2020) 23, 101709, pp. 1-20. [cited by applicant]
Fishwild et al., “Human lgG kappa antigen-specific high affinity monoclonal antibodies from transgenic mice,” Faseb Journal. (vol. 12. No. 4. pp A309) 9650 Rockville Pike, Bethesda, MD 20814-3998 USA: Federation Amer So… [cited by applicant]
Fishwild et al., “Human lgG kappa antigen-specific high affinity monoclonal antibodies from transgenic mice.” Journal of Allergy and Clinical Immunology. vol. 99. No. 1. pp S186, Abs 753. 11830 Westline Industrial Dr, S… [cited by applicant]
Fishwild et al. “High avidity human lgG monoclonal antibodies from novel strains of minilocus transgenic mice.” Antibody Engineering II. New Technology, Application & Commercialization (W. Hori, Ed.) (1997): 187-211. [cited by applicant]
Presta, “Antibody engineering,” Curr Opin Biotechnol. (1992) 3(4):394-8. [cited by applicant]
Zhongguo et al. “Construction of pcDNA3.1(+)/A2E eukaryotic expression vector and its expression on K562 cell,” (2005) 13:464-467. (Article in Chinese), English Abstract only. [cited by applicant]
Lee et al., “Epigenetic Modification and Antibody-Dependent Expansion of Memory-like NK Cells in Human Cytomegalovirus-Infected Individuals,” Immunity (2015) 42:431-442. [cited by applicant]
Zhang et al., “Cutting Edge: Antibody-Dependent Memory-like NK Cells Distinguished by FcRγ Deficiency,” J. Immunol. (2013) 190(4):1402-1406. [cited by applicant]
Beziat et al., “CMV drives clonal expansion of NKG2C1NK cells expressing self-specific KIRs in chronic hepatitis patients,” Eur. J. Immunol. (2012) 42: 447-457. [cited by applicant]
Binyamin et al., “Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy,” J Immunol. (2008) 180(9): 6392-401. [cited by applicant]
Brandt et al., “The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans,” Journal of Experimental Medicine (2009) 206(7): 1495-1503 (2009). [cited by applicant]
Childs et al., “Bringing Natural Killer Cells to the Clinic: Ex Vivo Manipulation,” American Society of Hematology (2013) 2013:234-246. [cited by applicant]
Cichocki et al., “CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT,” Leukemia. (2016) 30(2):456-463, 18 pages. [cited by applicant]
Cichocki et al., “GSK 3 inhibition drives maturation of NK cells and enhances their antitumor activity,” Cancer Res. (2017) 77(20): 5664-5675. [cited by applicant]
Cichocki et al., “The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer,” Curr Top Microbiol Immunol. (2016) 395: 225-243, 19 pages. [cited by applicant]
Costa-Garcia et al., “Antibody-Mediated Response of NKG2Cbright NK Cells against Human Cytomegalovirus,” J Immunol (2015) 194(6): 2715-2724. [cited by applicant]
Dubois et al., “Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action,” J Immunol. (2008) 180(4): 2099-106. [cited by applicant]
Fiegler et al. “Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.” Blood, The Journal of the American Society of Hematology (2013) 122.5: 684-693. [cited by applicant]
Kim et al., “HLA alleles determine differences in human natural killer cell responsiveness and potency,” PNAS (2008) 105(8): 3053-3058. [cited by applicant]
Kucuksezer et al., (2021). “The role of natural killer cells in autoimmune diseases.” Frontiers in immunology 12:622306, 23 pages. [cited by applicant]
Lee et al., “Site-specific integration in CHO cells mediated by CRISPR/Cas9 and homology-directed DNA repair path,” Sci. Rep, (2015) 5:8572, 11 pages. [cited by applicant]
Li et al., “Optimization of genome engineering approaches with the CRISPR/Cas9 system,” PLoS One (2004) 9:e105779, 10 pages. [cited by applicant]
Lopez-Verges et al., “Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection,” PNAS (2011) 108(36): 14725-14732. [cited by applicant]
Qian et al. “Advancements in the Study of the Immune Molecule NKp46 in Immune System-related Diseases.” Clinical reviews in allergy & immunology (2024) 67: 96-110. [cited by applicant]
Romee et al. “NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM 17).” Blood (2013) 121(18): 3599-608. [cited by applicant]
Sivori et al., “NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, … [cited by applicant]
Takai et al. “FcR gamma chain deletion results in pleiotrophic effector cell defects.” Cell. (1994) 76(3):519-29, 12 pages. [cited by applicant]